Brand-name drug
Belbuca price, strengths & recalls
Brand of buprenorphine (generic)
Pharmacies pay $453.27 for 60 films of Belbuca 0.15 mg buccal film this week, and from $452.47 to $1,115.29 across its 7 priced strengths and forms. The generic, buprenorphine, costs pharmacies from $8.62. It has 29 recalls on record, none ongoing. Its official label last changed on January 6, 2026.
Brand- Fair cash price
- $531.76
- Strengths
- 7
- Makers
- 1
- Updated
- Nov 11
Belbuca price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.075 mg buccal film Brand | $7.54 | $452.47 / 60 films |
| 0.15 mg buccal film Brand | $7.55 | $453.27 / 60 films |
| 0.3 mg buccal film Brand | $11.86 | $711.42 / 60 films |
| 0.45 mg buccal film Brand | $16.11 | $966.74 / 60 films |
| 0.6 mg buccal film Brand | $17.18 | $1,031.06 / 60 films |
| 0.75 mg buccal film Brand | $18.09 | $1,085.33 / 60 films |
| 0.9 mg buccal film Brand | $18.59 | $1,115.29 / 60 films |
Belbuca vs generic buprenorphine
GenericBuprenorphine pricesSupply status: shortages & recalls
Recalls
Showing the 6 most relevant of 29 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Belbuca
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use BELBUCA safely and effectively. See full prescribing information for BELBUCA. BELBUCA® (buprenorphine buccal film), CIII Initial U.S. Approval: 1981
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BELBUCA
WARNING: SERIOUS LIFE-THREATENING RISKS FROM USE OF BELBUCA
See full prescribing information for complete boxed warning.
BELBUCA exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. (5.1)
Serious, life-threatening, or fatal respiratory depression may occur, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of BELBUCA are essential. Instruct patients on proper administration of BELBUCA to reduce the risk. (2.1, 2.8, 5.2)
Accidental exposure to BELBUCA, especially in children, can result in fatal overdose of buprenorphine. (5.2)
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.3, 7)
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (5.4)
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (5.5)
Addiction, Abuse, and Misuse
Because the use of BELBUCA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1)].
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of BELBUCA, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of BELBUCA are essential. Misuse or abuse of BELBUCA by chewing, swallowing, snorting, or injecting buprenorphine extracted from the buccal film will result in the uncontrolled delivery of buprenorphine and pose a significant risk of overdose and death [see Dosage and Administration (2.1, 2.8), Warnings and Precautions (5.2)].
Accidental Exposure
Accidental exposure of even one dose of BELBUCA, especially in children, can result in a fatal overdose of buprenorphine [see Warnings and Precautions (5.2)].
Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of BELBUCA and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3), Drug Interactions (7)].
Neonatal Opioid Withdrawal Syndrome (NOWS)
Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.4)].
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.5)].
Recent major changes (as listed on the label)
Boxed Warning | 12/2025 |
Indications and Usage (1) | 12/2025 |
Dosage and Administration (2.2, 2.3, 2.5) | 12/2025 |
Warnings and Precautions (5.1, 5.2, 5.3, 5.12, 5.17) | 12/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA207932 · Bdsi
- First approved
- October 23, 2015 (11 years ago)
- Latest approved change
- June 18, 2026
- Approved label
- PDF, Jan 5, 2026
- Generic makers
- 17 approved generic applications on the market
- Last patent listed
- December 21, 2032
Belbuca questions
How much does belbuca cost without insurance?
Pharmacies pay about $453.27 for 60 films of belbuca 0.15 mg buccal film ($7.55 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $531.76. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Belbuca?
Yes: buprenorphine. Pharmacies pay from $8.62 for it. Compare buprenorphine prices.
Is belbuca in shortage?
No shortage is reported for belbuca right now. We check the national shortage list every day.
Has belbuca been recalled?
29 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the belbuca label last change?
The official label was last updated on January 6, 2026 (version 18). See what changed.
Talk about belbuca
No comments yet. Questions, tips, what worked for you - start the conversation.